Conclusions & Recommendations
18.16.1 - DRC
Conclusion/Recommendation:
TEC recommends to ITI management to offer technical assistance for program and supply chain capacity development in close coordination with the National Program at national and provincial levels.
Action:
ITI is working with the National Program to plan supply chain strengthening trainings and ensure that Zithromax® supply chain capacity building will be included in training of distributors at the Health Zone level.
TEC 18
2018
Africa - Central/Southern
DRC
supply chain, recommendations for ITI management
18.17.1 - Zambia
Conclusion/Recommendation:
TEC recognizes there are a number of districts without up-to-date prevalence information, and encourages the Zambian MOH to consider additional surveys in Limulunga and Mongu in Western Province.
Action:
The recommendation was shared with the National Program.
TEC 18
2018
Africa - Central/Southern
Zambia
surveys, suspected endemic
18.17.2 - Zambia
Conclusion/Recommendation:
TEC further encourages the National Program to submit a Zithromax® request in any districts where future prevalence surveys indicate that treatments are warranted.
Action:
The recommendation was shared with the National Program.
TEC 18
2018
Africa - Central/Southern
Zambia
18.18.1 - Zimbabwe
Conclusion/Recommendation:
TEC encourages the National Program to submit a Zithromax® request to ITI as data become available following baseline surveys in any areas that warrant treatment.
Action:
The recommendation was shared with the National Program.
TEC 18
2018
Africa - Central/Southern
Zimbabwe
evaluation units
18.19.1 - Yemen
Conclusion/Recommendation:
Because Kamaran was not included in surveyed evaluation units, TEC recommends that the 2019 drug decision is “Does not meet Criteria” and that Kamaran be included in the EU for upcoming impact surveys in Al Mighlaf, Al Munirah, As Salif, and Az Zaydiyah in Al Hudaydah.
Action:
The recommendation was shared with the National Program.
TEC 18
2018
Eastern Mediterranean
Yemen
evaluation units, Zithromax® donation criteria
18.2.1 - Zithromax® for Refugees: Decision Making Flowchart
Conclusion/Recommendation:
TEC endorses the Refugee Decision Making Flow Chart presented at TEC 18 and recommends to ITI management to communicate the decision making process to country programs and partners, where relevant.
Action:
This information is being provided to national programs where applicable in conjunction with their 2020 applications.
TEC 18
2018
special populations, Zithromax® donation criteria
18.3.1 - Surveillance for Recrudescence
Conclusion/Recommendation:
TEC recommends to ITI to continue supporting opportunities to conduct longitudinal surveillance of populations no longer warranting MDA in a variety of geographical and epidemiological settings.
Action:
ITI Management have discussed a variety of operational research options with researchers who have experience in this field, and where opportunities exist for building off of existing longitudinal studies. We will seek the input of the TEC in the closed door session as to whether this constitutes a topic of sufficient importance to allocate Scale Up funds to ensure this is done in a timely fashion.
TEC 18
2018
end game, research
18.4.1 - New Zithromax® Dosing
Conclusion/Recommendation:
Following roll-out of the new Zithromax® dosing recommendations, TEC recommends ITI monitor to ensure correct POS and tablet stock provision from Pfizer and gather feedback from implementing partners and National Programs.
Action:
ITI Supply Chain team is working in close coordination with each National Program to ensure adequate POS provision, recognizing that adjustments may be needed over time. Pfizer has committed to sending supplemental POS shipments to countries, should the need arise.
In addition, the Ethiopia program will carry out operational research to determine the actual mean dose of Zithromax® tablets for older children and adults and the mean dose of POS for children to facilitate accurate stock forecasting. The research will take place in November in three regions (Amhara, Oromia, and SNNP).
TEC 18
2018
dosing, supply chain, recommendations for ITI management
18.4.2 - New Zithromax® Dosing
Conclusion/Recommendation:
TEC recommends ITI share the new guidelines with National Programs with immediate effect to facilitate roll out.
Action:
ITI has communicated the dosing changes to all National Programs and partners in a letter in July, through presentations at the regional meetings in July and August, and the ICTC meeting in September. Countries have been requested to implement the changes as soon as practical.
TEC 18
2018
dosing
18.5.1 - Cameroon
Conclusion/Recommendation:
TEC recommends population-based prevalence surveys in Kolofata to determine whether the district has reached the elimination goals. If the district warrants treatment, TEC encourages the National Program to submit a mid-year request for Zithromax® to ITI as soon as the data become available.
Action:
The recommendation has been shared with the National Program.
TEC 18
2018
Africa - West
Cameroon